CriticalSelective If channel inhibitor of the sinoatrial node×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
In the liver and gut, only the enzyme CYP3A4 breaks down ivabradine, and posaconazole is a strong inhibitor of this enzyme (ivabradine and posaconazole summaries of product characteristics, SmPCs, European Medicines Agency, EMA). No study has looked at this pair directly. The strong CYP3A4 inhibitors ketoconazole 200 mg once daily and josamycin 1 g twice daily raised mean ivabradine exposure 7- to 8-fold. High ivabradine levels carry a risk of excessive bradycardia (ivabradine SmPC, EMA). The second route is the QT interval on the electrocardiogram. Posaconazole prolongs the QT interval and has caused torsade de pointes (posaconazole label, US Food and Drug Administration, FDA). The slower heart rate caused by ivabradine can make QT prolongation worse (ivabradine SmPC, EMA).
Symptoms
Excessive bradycardia shows as a resting heart rate persistently below 50 beats per minute, dizziness, fatigue and low blood pressure (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). Sinus arrest and heart block can occur (ivabradine label, US Food and Drug Administration, FDA). Bradycardia together with a prolonged QT interval on the electrocardiogram raises the risk of severe ventricular arrhythmia, including torsade de pointes (ivabradine label, FDA). The posaconazole SmPC lists torsade de pointes, sudden death and cardiorespiratory arrest among the rare adverse reactions to posaconazole itself (posaconazole SmPC, EMA).
Management
The US ivabradine label contraindicates all strong inhibitors of the enzyme CYP3A4 and names azole antifungals among them (US Food and Drug Administration, FDA). Posaconazole is a strong inhibitor of this enzyme (posaconazole label, FDA, and summary of product characteristics, SmPC, European Medicines Agency, EMA), so the combination is contraindicated. The European ivabradine SmPC (EMA) also says to avoid drugs that prolong the QT interval on the electrocardiogram (ECG). The US posaconazole label (FDA) states that posaconazole prolongs the QT interval. Pause ivabradine for the whole course of posaconazole (follows from the contraindication). The documents give no waiting time between stopping posaconazole and restarting ivabradine. The mean half-life of posaconazole tablets is 29 hours (posaconazole SmPC, EMA). Restart ivabradine only if the resting heart rate, based on repeated measurements, an ECG or 24-hour monitoring, is at least 70 beats per minute (ivabradine SmPC, EMA). Check potassium, magnesium and calcium before and during posaconazole treatment and correct them as needed (posaconazole SmPC, EMA). If the two drugs have already been taken together, pause ivabradine and monitor the heart closely, including heart rate and ECG (ivabradine SmPC, EMA). Treat severe bradycardia with poor haemodynamic tolerance in a specialised setting with intravenous beta-stimulants such as isoprenaline and, if needed, temporary cardiac pacing (ivabradine SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Noxafil (posaconazole) prescribing information (2026)– FDA, DailyMed, Noxafil (Merck Sharp & Dohme), setid b073b082-7b57-4423-8c06-4fd4263d6f84, versión 56, revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5, 5.2 y 7.2
- AEMPS: Ficha técnica de Noxafil 100 mg comprimidos gastrorresistentes (posaconazol) (2026)– AEMPS, CIMA (texto EMA), nº registro 105320002, secciones 4.3 y 4.5
- EMA: Ficha técnica: Ivabradina – Procoralan (EU/1/05/316), sección 4.3 (2025)– EMA, SmPC Procoralan (EU/1/05/316), texto en CIMA nº 05316003, información del producto actualizada 17/11/2025, secciones 4.3, 4.4 y 4.5
- FDA: Corlanor (ivabradine) prescribing information (2025)– FDA, DailyMed, Amgen, setid 92018a65-38f6-45f7-91d4-a34921b81d0d, v33, 11/2025, sections 2.1, 4, 5.3, 7.1 and 7.2